Name: Anlotinib (AL3818) Dihydrochloride
Brand: Selleck Chemicals
SKU: S8726
Availability: InStock
Rating: 5 (49 reviews)

Jump to

Quality Control

Batch: Purity: 99.93%

99.93

Related Targets	EGFR FGFR PDGFR c-Met Src MEK CSF-1R FLT3 HER2 c-Kit
Other VEGFR Inhibitors	SAR131675 SU 5402 Cediranib (AZD2171) Vatalanib (PTK787) 2HCl Linifanib (ABT-869) Apatinib (YN968D1) Apatinib (YN968D1) mesylate Ki8751 Semaxanib (SU5416) ZM 323881 HCl

Cell Culture, Treatment & Working Concentration

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
U-87MG	Function assay	0.01, 0.1, 1, 10 and 100 μM	1.5 h	inhibited PDGF-BB-stimulated phosphorylation of PDGFRβ, AKT and ERK in U-87MG cells	29446853
Mo7e	Function assay	0.01, 0.1, 1, 10 and 100 μM	1.5 h	Anlotinib inhibited SCF‐1‐stimulated phosphorylation of c‐Kit, AKT and ERK in Mo7e cells	29446853
HUVEC	Function assay	0.01, 0.1, 1, 10 and 100 μM	1.5 h	anlotinib inhibited VEGF‐stimulated intracellular phosphorylation of VEGFR2 in a concentration‐dependent way in HUVEC with a subnanomolar IC50 value	29446853
A549	Cell viability assay		24, 48 and 72 h	IC50=64.82 μM（t=24 h）; IC50=30.34 μM（t=48 h）; IC50=17.29 μM（t=72 h）	30755242
NCI-H1975	Cell viability assay	8 μg/ml	24 h	Cell viability was decreased remarkably	30871526
Calu-1	Cell viability assay		24, 48 and 72 h	IC50=61.23 μM（t=24 h）; IC50=36.8 μM（t=48 h）; IC50=28.64 μM（t=72 h）	30755242
Click to View More Cell Line Experimental Data

Solubility

In vitro
Batch:

Water : 96 mg/mL

DMSO : 48 mg/mL (99.92 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.250mg/ml (2.60mM)	Taking the 1 mL working solution as an example, add 50 μL 25 mg/ml clarified DMSO stock solution to 400 μL PEG300, mix evenly to clarify it; add 50 μL Tween80 to the above system, mix evenly to clarify it; then continue to add 500 μL ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	480.36	Formula	C₂₃H₂₂FN₃O₃.2HCl	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	1360460-82-7	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			SMILES	CC1=CC2=C(N1)C=CC(=C2F)OC3=C4C=C(C(=CC4=NC=C3)OCC5(CC5)N)OC.Cl.Cl

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	VEGFR2 (Cell-free assay) 0.2 nM VEGFR3 (Cell-free assay) 0.7 nM c-Kit (Cell-free assay) 14.8 nM c-Kit (Cell-free assay) 14.8 nM c-Kit (Cell-free assay) 14.8 nM
In vitro	Anlotinib occupies the ATP-binding pocket of VEGFR2 tyrosine kinase and shows high selectivity and inhibitory potency (IC 50 <1 nmol/L) for VEGFR2 relative to other tyrosine kinases. Anlotinib inhibits VEGFR2 and VEGFR3 with IC50 values of 0.2 and 0.7 nmol/L, respectively. The inhibitory potency of anlotinib against VEGFR1 is lower, with an IC50 value of 26.9 nmol/L. The IC50 values of anlotinib for inhibition of the PDGFR-related kinases c-Kit and PDGFRβ are 14.8 and 115.0 nmol/L, respectively. Anlotinib has little effect on the activity of other kinases, including c-Met, c-Src, EGFR and HER2, even at a concentration of 2000 nmol/L. Anlotinib inhibits VEGF-induced signaling and cell proliferation in HUVEC with picomolar IC50 values. However, micromolar concentrations of anlotinib are required to inhibit tumor cell proliferation directly in vitro. Anlotinib significantly inhibits HUVEC migration and tube formation; it also inhibits microvessel growth from explants of rat aorta in vitro.
Kinase Assay	Enzyme-linked immunosorbent assay
Kinase Assay	Inhibitory activity of anlotinib against tyrosine kinases was determined using ELISA. Reaction of ATP with tyrosine kinase was initiated in reaction buffer (50 mmol/L HEPES pH 7.4, 50 mmol/L MgCl₂, 0.5 mmol/L MnCl₂, 0.2 mmol/L Na₃VO₄, 1 mmol/L DTT) and incubated for 1 hour at 37°C in 96-well plates precoated with 20 μg/mL Poly(Glu,Tyr)4:1. The plate was incubated with PY99 antibody and then with HRP-conjugated anti-mouse IgG. After reaction with o-phenylenediamine solution and then termination with the addition of 2N H₂SO₄, absorbance was measured at 490 nm using a Synergy H4 Hybrid reader.
In vivo	Anlotinib decreases vascular density in tumor tissue in vivo. Compared with the well-known tyrosine kinase inhibitor sunitinib, once-daily oral dose of anlotinib shows broader and stronger in vivo antitumor efficacy and, in some models, causes tumor regression in nude mice. It is well-tolerated in mice. Anlotinib is efficacious at doses (1.5‐6 mg/kg daily) that are significantly lower than effective doses of other TKI, which require doses of 20‐100 mg/kg to achieve significant inhibition of tumor growth in mice. In vivo, anlotinib has showed broad activity against human tumor xenograft models of the colon (SW-620), ovarian (SK-OV-3), liver (SMMC-7721), renal (Caki-1), glioma (U87MG), and non-small cell lung (Calu-3) during dosing period. In Sprague-Dawley rats and beagle dogs, anlotinib is rapidly absorbed from the gastrointestinal tracks after oral administration. The oral bioavailability is 23-45 % in rats and 47-74 % in dogs. Anlotinib exhibits large volume of distribution in both species. In rats, primary tissues, such as the lung, kidneys, liver, and heart, exhibit significant higher exposure levels to anlotinib compared with that in plasma. The exposure level in the brain is comparable with the corresponding plasma level. In tumor-bearing mice, anlotinib concentrates 2.4-2.6 times in tumor tissue than in plasma. In human, anlotinib exhibits a quite long t_1/2 (96 ± 17 h), which appeared to be dose-independent. The terminal half-life of anlotinib in dogs (22.8±11.0 h) is longer than that in rats (5.1±1.6 h). This difference appeares to be mainly associated with an interspecies difference in total plasma clearance (rats, 5.35±1.31 L/h/kg; dogs, 0.40±0.06 L/h/kg). In human plasma, anlotinib is predominantly bound to albumin and lipoproteins, rather than to α1-acid glycoprotein or γ-globulins.
References	[1] https://pubmed.ncbi.nlm.nih.gov/29446853/ [2] https://pubmed.ncbi.nlm.nih.gov/27716285/ [3] https://pubmed.ncbi.nlm.nih.gov/29620050/

Applications

Methods	Biomarkers	PMID
Western blot	TP53 / Cleaved-caspase 3 / Cleaved PARP Beclin-1 / LC3-I / LC3-II Akt / p-Akt / mTOR / p-mTOR	30139768
Immunofluorescence	LC3-II	30755242
Growth inhibition assay	Cell viability	30755242

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-04-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07540390	NOT_YET_RECRUITING	Nasopharyngeal Carcinoma	Sun Yat-sen University	2026-05-08	PHASE3
NCT07612098	NOT_YET_RECRUITING	Soft Tissue Sarcoma (STS)	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	2026-07-01	PHASE2
NCT06992336	RECRUITING	Breast Cancer	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	2025-04-10	PHASE2
NCT07156643	NOT_YET_RECRUITING	Locally Advanced Soft Tissue Sarcoma	The First Affiliated Hospital with Nanjing Medical University	2025-10-01	PHASE2
NCT07520760	RECRUITING	HER 2 Negative Breast Cancer	Sun Yat-sen University	2026-04-01	PHASE2
NCT07193186	NOT_YET_RECRUITING	Thyroid Cancer	Fudan University	2026-04-01	PHASE2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Anlotinib (AL3818) Dihydrochloride VEGFR2 Inhibitor

Chemical Structure

Molecular Weight: 480.36